GHR Foundation
  • Impact Areas
    • Global Engagement >
      • Children in Families
      • Prepare The Future
      • Programs in Transition >
        • BridgeBuilder >
          • Overview
          • 2017 Top Ideas >
            • Peace Direct
            • BioCarbon Engineering
            • LIFT Chicago
            • Local Youth Corner Cameroon
            • NaTakallam
          • 2018 Top Ideas >
            • This is My Backyard
            • Found in Translation
            • Producers Direct
            • War Child Canada
            • My Choices Foundation
          • 2019 Top Ideas >
            • Top Manta
            • Five One Labs
            • SAMA for All
            • Talent Beyond Boundaries
            • FaithAction
        • Inter-Religious Action
        • Sister Support
    • Education >
      • Catholic Schools
      • Higher Education
    • Twin Cities Racial Equity
    • Alzheimer's
  • News
  • About Us
    • The Foundation
    • History & Legacy
    • Team >
      • Staff
      • Committees
      • Board
    • FAQs
    • Grants & Financials
  • Contact

How the Collaboration for Alzheimer’s Prevention is Improving Trials

1/7/2016

 
Picture
GHR’s Health Initiative has committed more than $17 million over 5 years to scaling up important Alzheimer’s disease prevention research already underway. The Foundation is targeting funding to improve some of the largest research efforts in the field, including Washington University's DIAN-TU Study, which is quickly evaluating potential prevention treatments among those who are most likely to develop the disease, and Harvard University's A4 Study, which is working toward FDA approval for prevention therapy in the general population.

A recent Nature article highlights the importance of preclinical treatments, like DIAN-TU, which are initiated in cognitively unimpaired at-risk people, and are intended to postpone, reduce the risk of or completely prevent the clinical onset of Alzheimer’s. The authors argue that we need faster ways to evaluate these treatments, new ways to collaborate towards common goals and determination to expedite preclinical trials.

One useful tool for accelerating the initiation and performance of these trials is Collaboration for Alzheimer’s Prevention (CAP), a convening and consensus-building initiative co-founded by DIAN-TU and A4, among others. Important strides made by CAP include:
  • Development of trial outcomes, including cognitive and clinical endpoints and biomarkers
  • Standardization of sample and data collection, such as the use of tau imaging in all CAP trials
  • Participant recruitment and retention through the development of a registry
  • Data and sample sharing mechanisms

​These developments help carry out Alzheimer’s prevention trials with care, thoroughness and maximum impact. ​While all research is uncertain, the potential to turn the tide and provide hope for all families that face Alzheimer’s has never been more promising.  To learn more about GHR’s Alzheimer’s prevention funding efforts, contact us.

Alzheimer's Research Making Headlines

4/6/2015

1 Comment

 
Picture
From People Magazine: Alzheimer’s patient Sonia Cardona and her caregiver and daughter Daisy Duarte.
The fight against Alzheimer’s disease is making headlines. Fueled by research advances and popular culture attention, GHR-funded projects targeting Alzheimer's prevention are building public awareness. Grants making headlines include:
  • DIAN-TU Study: GHR is one of the funders of the Washington University study to quickly evaluate potential prevention treatments among people most likely to develop the disease. Trial participant Daisy Duarte was recently profiled in People Magazine. This article, along with Oscar attention for “Still Alice”—a film about a woman with early-onset Alzheimer’s—is helping to bring prevention research into the public spotlight.
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Study (A4): GHR is also contributing to the A4 Harvard study that is designed to identify and treat patients in the earliest stages of Alzheimer's, before memory loss begins. Recently, A4 researchers conducted the first scans in a clinical trial for the presence of the protein tau, which forms toxic tangles of nerve fibers associated with Alzheimer's. The addition of tau imaging into this trial was directly funded by GHR and is our primary contribution to the study. The breakthrough scans will enable researchers to see the effects of an experimental drug on both amyloid plaques and tau tangles for the first time, potentially leading to more effective prevention and treatments.

Recent headlines document important milestones in the fight against Alzheimer's. GHR supports research that inspires hope among those impacted by the disease and advances opportunities for real results. For more information, contact us.
1 Comment

Alzheimer’s Prevention Progress Presented at Clinical Trials Conference

12/23/2014

0 Comments

 
Picture
Recently more than 700 Alzheimer’s disease researchers attended the seventh annual Clinical Trials in Alzheimer’s Disease (CTAD) Conference in Philadelphia to discuss new developments in the field. In a press release describing the conference, CTAD described two highlights: new investigational compounds and collaborations for Alzheimer’s prevention.

The latter described the progress made by the Collaboration for Alzheimer’s Prevention (CAP), an umbrella group including two studies funded, in part, by GHR—the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study and the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).

At the conference, director of DIAN-TU Randall Bateman spoke on the progress of the CAP partnership. Despite differences in populations, the four studies have found common ground on a clear set of cognitive domains to test and compare results. All CAP trials now also plan to use tau imaging, thanks to a partnership between the NIH and 10 industry partners.

CAP’s updates, while notable, are only a portion of the rapidly changing landscape of Alzheimer’s research. Other notable progressions presented at CTAD, such as the new compounds being developed and the creation of the Alzheimer’s Prevention Registry to accelerate enrollment in trials, will intersect with GHR’s Health Initiative’s involvement as organizations and researchers work together to find effective treatment.
0 Comments

Enrollment Begins for GHR-Funded A4 Study on Alzheimer’s Treatment

10/29/2014

 
Picture
GHR Foundation’s Health Program funds research to support the prevention of Alzheimer’s disease. The FoundationFuondation             has committed more than $10 million over the next 5 years to scale up important research already underway, including some of the largest research efforts in the field.

One such research program is the A4 Study. This study, led by Harvard researcher Dr. Reisa Sperling and coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego, is a clinical trial focused on determining the effectiveness of prevention therapy before Alzheimer's disease impacts the brain.

Enrollment for the study is underway and researchers are currently looking for volunteers aged 65+ with normal memory function to be screened for an Alzheimer’s amyloid plaques. Those found eligible for the study will receive prevention treatment at locations across North America and Australia.

While all research is uncertain, the potential to turn the tide and provide hope for all families that face Alzheimer’s has never been more promising. If you know someone who might be qualified and interested in participating in the study, have them examine the eligibility requirements and learn more here. To learn more about partnering with GHR Foundation to fund innovative Alzheimer’s research, contact us.

GHR Supports Research Grant to Expand A4 Alzheimer’s Prevention Trial

3/5/2014

0 Comments

 
Picture
Photo credit: The Mayo Clinic
With a focus on Alzheimer’s disease prevention research, GHR Foundation funded a groundbreaking Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study which may help identify people who are highest risk to develop the disease. This research will also identify treatments – and when to best administer them – to slow or prevent Alzheimer’s. Long-term, the Foundation hopes the A4 study and complementary research will result in FDA approval for Alzheimer’s prevention therapies.

The A4 study team is continuing to develop the clinical partnerships necessary to study 1,000 patients and has created tools to share background with potential participants. GHR Alzheimer’s advisory board member and lead A4 researcher Dr. Reisa Sperling explains the research and how people can get involved in the research in a recent YouTube video. 

GHR looks forward to learning more about the impact of A4 on early detection and treatment of Alzheimer’s disease.  

0 Comments

    Categories

    All
    A4
    Africa
    Alzheimer's
    Alzheimer's Association
    Annual Report
    BridgeBuilder
    C2N
    Cambodia
    Catholic Schools
    Central African Republic
    Children In Families
    Coverage
    COVID 19
    COVID-19
    Design Build
    Develop Diagnostics
    DIAN
    DIAN Primary Prevention
    DIAN TU
    DIAN-TU
    Education
    Faith & Development
    Global
    Global Development
    Health
    Higher Education
    Inter-Religious Action
    Kenya
    La Jolla Institute
    Legacy
    Mayo Clinic
    Mayo Clinic Study Of Aging
    Myanmar
    Nepal
    Nigeria
    NIH NIA
    NIH-NIA
    Observational Studies
    Podcast
    PrecivityAD
    Prevention Trials
    Sister Support
    Solutions
    Twin Cities Racial Equity
    Uganda
    U.S.
    Work Of The Church
    Zambia

    Archives

    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    October 2019
    September 2019
    August 2019
    July 2019
    May 2019
    April 2019
    March 2019
    December 2018
    November 2018
    October 2018
    September 2018
    June 2018
    May 2018
    April 2018
    February 2018
    January 2018
    November 2017
    October 2017
    August 2017
    July 2017
    May 2017
    April 2017
    March 2017
    January 2017
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    August 2014
    July 2014
    May 2014
    April 2014
    March 2014
    October 2013
    December 2012

    RSS Feed

CONNECT WITH US

IMPACT AREAS  |  NEWS  |  ABOUT  |  JOBS  | ​ CONTACT  
Privacy Policy  |  Terms of Use
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2022 GHR FOUNDATION
All Rights Reserved.